Atormac
brintellex
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 2903  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
  »  Article in PDF (591 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

 
  In this Article
 »  Abstract
 »  Indications for ...
 »  Stereotactic Rad...
 »  Linear Accelerat...
 »  Fractionated Ste...
 »  Complications of...
 » Hypopituitarism
 »  Radiation-Induce...
 »  Radiation-Induce...
 »  Rare Complicatio...
 » Conclusion
 »  References

 Article Access Statistics
    Viewed400    
    Printed2    
    Emailed0    
    PDF Downloaded17    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents    
REVIEW ARTICLE
Year : 2020  |  Volume : 68  |  Issue : 7  |  Page : 129-133

Modern Methods of Stereotactic Radiosurgery and Radiotherapy for the Treatment of Cushing Disease


1 N.N. Burdenko National Medical Research Center of Neurosurgery; Department of Neurological Diseases and Neurosurgery, Peoples' Friendship University of Russia, Moscow, Russian Federation
2 Department of Neurological Diseases and Neurosurgery, Peoples' Friendship University of Russia, Moscow, Russian Federation

Date of Web Publication24-Jun-2020

Correspondence Address:
Dr. Ashraf Abdali
4th Tverskaya Yamskaya 16, Moscow Russia 125047. 8th, Neurosurgical Department of Skull Base Basal Tumors
Russian Federation
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.287663

Rights and Permissions

 » Abstract 


Cushing's disease is caused by a pituitary tumor causing increased production of adrenocorticotropic hormone, which leads to chronic hypersecretion of cortisol through adrenal cortices. Endoscopic trans-sphenoidal adenomectomy is the first choice of treatment with greatest efficiency for the treatment of the disease. However, in the absence of remission or recurrence of hypercortisolism after neurosurgical resection (adenomectomy), as well as in cases when surgical intervention cannot be carried due to medical contraindications to surgical intervention, radiation treatment is used as an alternative or adjoining therapy. In this literature review the efficiency of different radiation techniques (the conventional and the modern techniques), as well as possible complications of modern methods of radiosurgery and radiotherapy have been looked for.


Keywords: Conventional-RT, Cushing disease, cyber-knife, fractionated stereotactic radiosurgery, gamma-knife, proton-therapy. stereotactic radiosurgery, radiotherapy
Key Message: The modern methods of Radiosurgery and Hypo fractionated radiosurgery allow us to achieve quicker remission in most patients with CD with minimal risk of complications. Is used as adjoining treatment to TSS or alternative treatment for variable severities of CD or as an alternative to bilateral adrenalectomy (in severe cases).


How to cite this article:
Abdali A, Astaf`eva L, Trunin Y, Kalinin P, Golanov A, Abdali B, Chmutin G, Shkarubo A, Chaurasia B. Modern Methods of Stereotactic Radiosurgery and Radiotherapy for the Treatment of Cushing Disease. Neurol India 2020;68, Suppl S1:129-33

How to cite this URL:
Abdali A, Astaf`eva L, Trunin Y, Kalinin P, Golanov A, Abdali B, Chmutin G, Shkarubo A, Chaurasia B. Modern Methods of Stereotactic Radiosurgery and Radiotherapy for the Treatment of Cushing Disease. Neurol India [serial online] 2020 [cited 2020 Jul 15];68, Suppl S1:129-33. Available from: http://www.neurologyindia.com/text.asp?2020/68/7/129/287663




It is severe neuroendocrine disorder associated with chronic hypersecretion of ACTH hormone caused by corticotroph-adenomas of pituitary gland. Increased secretion of ACTH causes hypersecretion of cortisol from the adrenal glands and induces endogenous hyper-cortisolism with clinical features of dysplastic obesity, hypertension, reproductive disorders, glucose metabolism disorders, osteoporosis, cognitive derangements, and behavioral changes. The first choice treatment method is trans-sphenoidal adenomectomy. Remission rates ranges from 65 to 90% even in specialized neuro-endocrinological centers. Radiation treatment modalities are considered second line treatment, in cases of incomplete surgical resection due to allocation of lesion in surgically non accessible allocations and no remission, in cases of recurrence after initial remission, and in cases when there are contraindication to surgical resection.[1] Use of radiation therapy to treat CD has a long history, Harvey Cushing was the first who treated Cushing disease by conventional radiation therapy. Following him, Alfred Pattison implanted radon seeds in the pituitary fossa in order to radiate and treat the lesion.[2] Modern methods of stereotactic radiation therapy includes radiosurgery, hypofractionated and standard fractionated radiation techniques, which have high precision with maximum conformity of radiation on the lesions and a minimum irradiation on the surrounding normal tissues. For planning a radiation therapy, the use of modern neuro-diagnostic techniques is very important. In this literature review the efficiency of different radiation techniques (conventional/modern techniques), and the possible complications of conventional/modern methods to treat Cushing disease have been looked for.


 » Indications for Stereotactic Radiosurgery and Radiotherapy of Cushing Disease Top


(1) Absence of remission after initial surgical resection, specifically when there is no lesion visible in postoperative follow-up MRI, and when the presence of other ectopic lesions is ruled out by specific investigations. (2) Lesions of Cushing disease which are not amendable to complete surgical resection or when lesions have pervasive behavior with invasion into the surrounding important anatomical structures. (3) For prophylaxis of Nelson's disease, after bilateral adrenalectomy. Radiation therapy can prevent the progressive growth of Corticotroph adenomas, which occurs in response to decrease in the inhibitory effect of cortisol. (4) Patients who cannot tolerate surgical procedure as a first line treatment. (5) In patients who are not willing to undergo surgery.[3],[4],[5]

Treatment of recurrent Cushing disease is challenging, repeat surgical resection is the method of choice, but repeat surgery is associated with even higher rates of recurrences in comparison to the primary surgery and is associate with other complications such as development of pan hypopituitarism, persistent diabetes insipidus, and higher rates of postoperative CSF leakages. Radiation therapy for the treatment of recurrence of Cushing disease is effective in around 2 / 3 of patients but also have associating complications which are discussed here in details.[6],[7]


 » Stereotactic Radiosurgery (SRS) for the Treatment of Cushing Disease Top


At present radiosurgery is widely used for the treatment of Cushing disease in the form of linear accelerator (Linac, Cyberknife), Gamma Knife, or Proton accelerators, which in spite the ability to control the growth of lesion simultaneously brings hormonal remission.[2],[7]

Gamma-knife

The first apparatus of Gamma Knife (GK; Elekta, Stockholm, Sweden) was developed by the Swedish neurosurgeon Leksell L. in 1951.[8] In this modality a high dose of radiation is delivered with high accuracy to the intracranial targets in a single session.

This modern method of SRS is effective in the treatment of Cushing disease and the remission rate according to different authors ranges between 35 and 83%.[7],[8] In one of the largest studies till date which included 278 patients followed for up to 15 years,[9] the control rate of hypercortisolism was reported close to 80% for gamma knife SRS and final remission was seen in 64% of cases in a period of 10 years. The most important finding of this study was the length of the mean time to reach anti-secretory efficacy which was 14.5 months which also showed that the drug therapy used for the control of hypercortisolims are used for a shorter period of time while awaiting the effects of radiotherapy.[4],[6],[9],[10] In a recent study performed by Joshua D et al., the simultaneous use of adrenalectomy with gamma knife was proposed in cases when severe hypercortisolism was present. The major factor for a simultaneous use of these both techniques was the need for acute control of hypercortisolism.[11] In the literature very little is found about the use of gamma knife radiosurgery as the first line of treatment, however in the study performed by Gautam et al., 22 patients were analyzed who underwent stereotactic hypophysectomy in different centers in the world and it was found that stereotactic hypophysectomy is efficient and the control of hypercortisolism was observed in 68% of patients.[9]


 » Linear Accelerator-Based Stereotactic Radiosurgery Top


There is very little written about the use of linear accelerators for the treatment of CD. In a study performed by P.J. Wilson carried to compare the results of linear accelerator method with the old conventional EBRT system, better tumor growth control of almost 83% and better control of hypercortisolism was shown with a significant faster control time after radiation in comparison to the older external beam radiation therapy (EBRT) system where the results of tumor growth control were 46%.[12] When analyzed on average after 66 months (range 0-183.6 months), biochemical remission was observed in 5.6% of patients (based on the level of cortisol in the blood) and in 22.2% of patients (based on the level of free cortisol in 24 hour urine collection).[12] In addition, 25–36.1% of patients showed biochemical improvement based on the level of cortisol in the blood or the level of free cortisol in 24 h urine collection, respectively.[12] Further studies are required to compare the efficacy of this stereotactic radiosurgery method in treating Cushing's disease and compare its use with the Gamma knife and cyberknife methods of treatments.

Cyberknife

Cyberknife (CK) is a robotic-based SRS system developed by Adler et al. in 1987.[13] In this system a linear accelerator which has 6 different free arm movement can target different targets without the use of stereotactic frames for radiation and can target different lesions in any localization.[14] Due to the greater prevalence of hormone-inactive pituitary adenomas, it is used after non-radical removal of lesions.[14] Possible complications are similar to other SRS methods (most often complication is the development of hypopituitarism).[15] Currently, there is little data on the use of the CK for the treatment of Cushing disease. In study carried by Moore JM for the treatment of CD, by CK when performed as an adjuvant therapy in patients with no remission or recurrence of hypercortisolism. Remission of hypercortisolism was achieved in 4 patients (57.1%) on average after 12.5 months post-radiation.[16]

Proton therapy

It is different radiation modality using high energy particle (protons instead of photons), which are losing their energy fairly slowly through the media it passes through, but then at sudden, at the end of their range of motion they lose whole bunch of energy at ones (Bragg peak effect) at the targeted location. In this form of radiation therapy exposure of normal brain tissue into radiation is extremely low and at the same time the target is receiving higher doses of radiation. It is believed that this modality will be more effective in large volume pituitary adenomas which requires treatment of the entire Sella or even extrasellar regions.[14] Proton therapy can be performed as single session fraction stereotactic radiosurgery (PSRS) or in multiple fractionated stereotactic radiotherapy sessions (PSRT). Proton therapy machines are very expensive, very heavy, and its maintenance is very difficult, not available everywhere and as such the price of treatment is also higher, only few centers have these machines worldwide but now it is getting popular and its use is growing for treatment of adenomas.[17] Very limited studies are present in literature about its use for the treatment of Cushing disease till yet. In a study carried by Joshua H et al., carried on 38 patients with the diagnosis of Cushing disease and Nilsson's syndrome, 52% (17) patient were in complete remission in a median time of 18 months (5–49 months) after treatment, and in a median follow-up of 62 months (range 20–136) in MRI no secondary tumors was noted and no clinical evidence of optic nerve damage, seizure, or brain injury was seen but all these patients developed new pituitary hormone deficits(hypopituitarism). This study concluded that PSRS is effective treatment modality with significant lower morbidity.[18] In another study performed in Russia in which 98 patient of Cushing disease underwent proton therapy with an exposure dose of 80–90 Gy (50–110), 90% of patient showed normal biochemical indices in the absence of any clinical signs of the disease. And in a follow-up after 3 and 5 years 94% patients remained in steady remission.[19]

In another study carried by Wattson DA et al. results of proton therapy of 144 patients, including 74 patients with Cushing disease, with a follow-up period of 52 months on average (6–247.2 months) in this study normalization of cortisol level was considered as biochemical remission, and MR signs of tumor absence or regression were considered as tumor control. Remission of hypercortisolism was achieved in 54% of patients on average after 32 months. Tumor growth control was achieved in 98% of patients. The appearance of hypopituitarism was observed in 45% and 62% of patients after 36 and 60 months, respectively. One patient developed Cranial Nerve III Palsy with subsequent regression; and in 3 patients, epileptic seizures (temporo-frontal) were observed.[20]


 » Fractionated Stereotactic Radiosurgery (FSRT) Top


Fractionate radiotherapy methods has some specific indications, it is used in cases of large pituitary adenoma cases when the risk of visual complications is proportional with the radiation dose which reaches the optic nerves, and definitely larger doses in single session radiotherapy imposes greater radiation to the optic apparatus compared to fractionated sessions and thus the fractionated stereotactic radiosurgery should be preserved for cases where lesions abuts the optic chiasms or optic nerves or either are bigger than 3 cm in size.[20],[21]

FSRT is carried out in 3-33 fractions with a total focal dose of 21–59.4 Gy. It is considered that, in contrast to convection radiation therapy, FSRT provides a more local radiation exposure with a minimum load on healthy surrounding tissues, reducing the risk of developing long-term radiation complications.[22],[23],[24],[25]

There is little data about the use of FSRT in the treatment of CD in the literature. In a study where 12 patients received FSRT after neurosurgical resection, hormonal remission was observed in 9 / 12 patients (75%) on average after 29 months of treatment, and the remission persisted in 56% of cases, during the follow-up period. In this study, no pituitary deficiency and other radiation complications were seen during the time under observation.[26]

In another study of 20 patients with persistent hypercortisolism after surgical adenomectomy, modern FSRT (LINAC) treatment was used at an average dose of 45 Gy, which was summed over 25 fractions, the tumor growth control was 95% with an average follow-up of 37.5 months (ranging from 12 to 144 months), hormonal remission was observed in 75% of patients after 20 months of observation.[24]


 » Complications of Radiation Therapy While Treating Cushing Disease Top


Despite the emergence of new and modern methods of radiation therapy, there is a risk of radiation induced complications while treating CD such as development of hypopituitarism, damage to surrounding nerves and blood vessels, malignant transformation of a benign lesions or the development of a secondary (radiation-induced) tumor.[17]


 » Hypopituitarism Top


Among the adverse effects of radiation therapy on pituitary lesions hypopituitarism is the most commonly met side effects and this is directly correlated to the length of time after radiation therapy. This complications are encountered in 29, 7% of cases (range 0–69%) by SRS radiotherapy at a mean time of 31 months (range 4–132 months). This is comparatively lower than the complications met with the older XRT method of radiation therapy which was 38.4% (range 0–58%).[27],[28],[29],[30] The rate of hypopituitarism is increased in longer periods after radiation, after 10 years it may raise up to 50–54%.[31] With the development of hypopituitarism, appropriate hormone replacement therapy is necessary. The ability to isolate the pituitary gland from the general tumor tissue while planning radiation therapy can reduce the radiation load on the normal gland and though minimize the risk of hypopituitarism development.


 » Radiation-Induced Injury Into the Visual Pathways Top


Even though that with the modern radiotherapeutical modalities the radiation-induced damage to the optic nerves has significantly decreased but still this complication can be met with higher doses of radiation into lesions located near to the optic apparatus. In order to decrease the occurrence of this complication maximal optic point dose should be kept in the range of (6–10 Gy) in SRS therapy which preserves damage into the optic apparatus. Radiation-induced damage to other intracranial nerves are very rare but could happen in cases when radiating lesions which are located laterally in the cavernous sinuses. Patient with repeat radiotherapeutical treatments and comorbidities such as prior injuries into the cranial nerves, diabetes mellitus, and vascular diseases are more prone to develop cranial nerve injuries.[32],[33],[34],[35]


 » Radiation-Induced Tumors Top


Radiation-induced secondary tumors are very rare, the incidence of such tumors decreased significantly after the development of newer radiation therapy modalities. In the conventional methods of radiation therapy the incidence of radiotherapy induced secondary lesions was 2–3% in 10–20 years period after radiation therapy and the most common tumors met were gliomas and meningioma's. Recently a large multicenter study was performed to analyze the rate of secondary intracranial malignancies and malignant transformation of benign tumors post-radiation therapy with the modern stereotactic radiosurgery methods. In this study 14,168 patients who underwent SRS for different benign lesion were included, the results concluded that the risk of malignant transformation or secondary intracranial malignancy remains low at long-term follow-up, and is similar to the risk predisposed to general population for the development of primary CNS tumors.[36]


 » Rare Complications of Radiation Therapies Top


In literature with the use of conventional method of radiation therapy, radiation-induced necrosis of temporal lobe has been reported but injury to the brain tissue while using the modern stereotactic radiotherapeutic methods is very rare even less the 1% cases. These could be clinically non-symptomatic ones or either present worsening the condition of patient. Risk of radiation-induced local injury into the brain tissue increases after a second course of radiation therapy. Carotid artery stenosis could also present sometimes as a very rare radiation-induced complication.

In an analysis of 331 cases of hormone-active and inactive pituitary adenomas treated using the traditional method of radiation therapy, a 5, 10, and 20-year risk of stroke was reported in 4, 11, and 21% of cases, respectively. The frequency of stroke was 4.1 times higher in comparison to normal general population.[17] In the work of Sherlock M et al., examining 501 patients with acromegaly which were treated with conventional radiation therapy and developed post-radiation hypocortisolism, a significant increase in the standardized mortality rate was found in comparison to general population. The increase in mortality was associated with cerebrovascular complications.[17]


 » Conclusion Top


Stereotactic radiation remains an effective treatment for patients with Cushing disease after non-radical surgical resection of lesion.

Both SRS and FSRT can provide good control of tumor growth in 85-100% of cases, and brings remission of hypercortisolims in up to 75% of cases, but relapse is still possible.

In modern clinical practices, SRS in a single dose of 16–25 Gy may be the most effective method of treatment for patients with Cushing disease with small pituitary adenoma, or in cases of residual tumor tissue in the cavernous sinuses after non-radical surgical adenomectomy. The use of FSRT is preferable for large tumors of the pituitary gland which are in close proximity or either involves the optic chiasm and nerves.

The use of SRS leads to a faster remission of hypercortisolism and a lower incidence of hypopituitarism.

All patients require drug therapy to control hypercortisolism before reaching the control of hypersecretion by radiation therapy, regardless of the method used for achieving this goal. After radiation therapy, a long-term (throughout life) observation is necessary to identify possible recurrences of Cushing disease, as well as the development of post-radiation complications.[37] Hypopituitarism is the most common late complication, while the frequency of other complications of radiation therapy is very low. In the case of hypopituitarism, appropriate hormonal replacement therapy is necessary.

Financial support and sponsorship

Rudn People Friendship University Grant Number.

Conflicts of interest

There are no conflicts of interest.



 
 » References Top

1.
Melnichenko GA, Dedov II, Belaya ZhE, Rozhinskaya LYa, Vagapova GR, Volkova NI, et al. Cushing disease: Clinic, diagnosis, diffrential diagnosis, treatment methodesProbl Endocrinol. T. 61:55-77. doi: https://doi.org/10.14341/probl201561255-77.  Back to cited text no. 1
    
2.
Pan L, Zhang N, Wang E, Wang B, Xu W. Pituitary adenomas: The effect of gamma knife radiosurgery on tumor growth and endocrinopathies. Stereotact Funct Neurosurg 1998;70(Suppl 1):119-26.  Back to cited text no. 2
    
3.
Oh KS, S HA, Loeffler JS. Radiation Therapy in the Management of Cushing's Disease. © Springer Science+Business Media, LLC; 2011.  Back to cited text no. 3
    
4.
Mehta GU, Lonser R. Management of hormone-secreting pituitary adenomas. Neuro Oncol 2017;19:762-73.  Back to cited text no. 4
    
5.
Starke RM, Williams BJ, Vance ML, Sheehan JP. Radiation therapy and stereotactic radiosurgery for the treatment of Cushing's disease: An evidence-based review. Curr Opin Endocrinol Diabetes Obes 2010;17:356-64.  Back to cited text no. 5
    
6.
Shepard MJ, Mehta GU, Xu Z, Kano H, Sisterson N, Su YH, et al. Technique of whole-sellar stereotactic radiosurgery for Cushing disease: Results from a multicenter, international cohort study. World Neurosurg 2018;116:e670-9.  Back to cited text no. 6
    
7.
Castinetti F, Brue T, Ragnarsson O. Radiotherapy as a tool for the treatment of Cushing's disease. Eur J Endocrinol 2019;180:D9-18.  Back to cited text no. 7
    
8.
Castinetti F, Nagai M, Dufour H, Kuhn JM, Morange I, Jaquet P, et al. Gamma knife radiosurgery is a successful adjunctive treatment in Cushing's disease. Eur J Endocrinol 2007;156:91-8.  Back to cited text no. 8
    
9.
Mehta GU, Ding D, Patibandla MR, Kano H, Sisterson N, Su YH, et al. Stereotactic radiosurgery for cushing disease: Results of an international, multicenter study. J Clin Endocrinol Metab 2017;102:4284-91.  Back to cited text no. 9
    
10.
Pivonello R, De Leo M, Cozzolino A, Colao A. The treatment of Cushing's disease. Endocr Rev 2015;36:385-486.  Back to cited text no. 10
    
11.
Hughes JD, Young WF, Chang AY, Link MJ, Garces YI, Laack NN, et al. Radiosurgical management of patients with persistent or recurrent Cushing disease after prior transsphenoidal surgery: A management algorithm based on a 25-year experience. Neurosurgery 2020;86:557-64.  Back to cited text no. 11
    
12.
Wilson PJ, Williams JR, Smee RI. Cushing's disease: A single centre's experience using the linear accelerator (LINAC) for stereotactic radiosurgery and fractionated stereotactic radiotherapy. J Clin Neurosci 2014;21:100-6.  Back to cited text no. 12
    
13.
Adler JR Jr, Chang SD, Murphy MJ, Doty J, Geis P, Hancock SL. The Cyberknife: A frameless robotic system for radiosurgery. Stereotact Funct Neurosurg 1997;69:124-8.  Back to cited text no. 13
    
14.
Brooke Swearingen BM, Cushing's Disease. Library of Congress Control Number: 2011932355. 2011. doi 10.1007/978-1-4614-0011-0.  Back to cited text no. 14
    
15.
Sheehan JM, Vance ML, Sheehan JP, Ellegala DB, Laws ER Jr. Radiosurgery for Cushing's disease after failed transsphenoidal surgery. J Neurosurg, 2000;93:738-42.  Back to cited text no. 15
    
16.
Moore JM, Sala E, Amorin A, Martinez H Jr, Bhowmik AC, Chang SD, et al. Cyberknife radiosurgery in the multimodal management of patients with Cushing disease. World Neurosurg 2018;112:e425-30.  Back to cited text no. 16
    
17.
Shih HA, Loeffler JS. Radiation therapy in acromegaly. Rev Endocr Metab Disord 2008;9:59-65.  Back to cited text no. 17
    
18.
Petit JH, Biller BM, Yock TI, Swearingen B, Coen JJ, Chapman P, et al. Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas. J Clin Endocrinol Metab 2008;93:393-9.  Back to cited text no. 18
    
19.
Marova EI, Starkova NT, Kirpatovskaia LE, Kolesnikova GS, Bukhman AI. [Results of treatment of Itsenko-Cushing disease using proton irradiation of the hypophysis]. Med Radiol 1987;32:42-9.  Back to cited text no. 19
    
20.
Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99:3933-51.  Back to cited text no. 20
    
21.
Iwata H, Sato K, Nomura R, Tabei Y, Suzuki I, Yokota N, et al. Long-term results of hypofractionated stereotactic radiotherapy with Cyberknife for growth hormone-secreting pituitary adenoma: Evaluation by the Cortina consensus. J Neurooncol 2016;128:267-75.  Back to cited text no. 21
    
22.
Minniti G, Clarke E, Scaringi C, Enrici RM. Stereotactic radiotherapy and radiosurgery for non-functioning and secreting pituitary adenomas. Rep Pract Oncol Radiother 2016;21:370-8.  Back to cited text no. 22
    
23.
McTyre E, Helis CA, Farris M, Wilkins L, Sloan D, Hinson WH, et al. Emerging indications for fractionated gamma knife radiosurgery. Neurosurgery 2017;80:210-6.  Back to cited text no. 23
    
24.
Budyal S, Lila AR, Jalali R, Gupta T, Kasliwal R, Jagtap VS, et al. Encouraging efficacy of modern conformal fractionated radiotherapy in patients with uncured Cushing's disease. Pituitary 2014;17:60-7.  Back to cited text no. 24
    
25.
Kim JO, Ma R, Akagami R, McKenzie M, Johnson M, Gete E, et al. Long-term outcomes of fractionated stereotactic radiation therapy for pituitary adenomas at the BC cancer agency. Int J Radiat Oncol Biol Phys 2013;87:528-33.  Back to cited text no. 25
    
26.
Colin P, Delemer B, Nakib I, Caron J, Bazin A, Bernard MH, et al. [Unsuccessful surgery of Cushing's disease. Role and efficacy of fractionated stereotactic radiotherapy]. Neurochirurgie 2002;48:285-93.  Back to cited text no. 26
    
27.
Ahmed SR, Shalet SM, Beardwell CG, Sutton ML. Treatment of Cushing's disease with low dose radiation therapy. Br Med J (Clin Res Ed) 1984;289:643-6.  Back to cited text no. 27
    
28.
Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Sutton ML. Long-term follow-up of low-dose external pituitary irradiation for Cushing's disease. Clin Endocrinol (Oxf) 1990;33:445-55.  Back to cited text no. 28
    
29.
Vicente A, Estrada J, de la Cuerda C, Astigarraga B, Marazuela M, Blanco C, et al. Results of external pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. Acta Endocrinol (Copenh) 1991;125:470-4.  Back to cited text no. 29
    
30.
Minniti G, Osti M, Jaffrain-Rea ML, Esposito V, Cantore G, Maurizi Enrici R. Long-term follow-up results of postoperative radiation therapy for Cushing's disease. J Neurooncol 2007;84:79-84.  Back to cited text no. 30
    
31.
Molitvoslovova NN. Acromegaly: Recent progress in diagnostics and treatment. Probl Endocrinol 2011;57:46-59. doi. https://doi.org/10.14341/probl201157146-59.  Back to cited text no. 31
    
32.
Rähn T, Thorén M, Hall K, Backlund EO. Stereotactic radiosurgery in Cushing's syndrome: Acute radiation effects. Surg Neurol 1980;14:85-92.  Back to cited text no. 32
    
33.
Stafford SL, Pollock BE, Leavitt JA, Foote RL, Brown PD, Link MJ, et al. A study on the radiation tolerance of the optic nerves and chiasm after stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 2003;55:1177-81.  Back to cited text no. 33
    
34.
Girkin CA, Comey CH, Lunsford LD, Goodman ML, Kline LB. Radiation optic neuropathy after stereotactic radiosurgery. Ophthalmology 1997;104:1634-43.  Back to cited text no. 34
    
35.
McArdle CB, Richardson CJ, Hayden CK, Nicholas DA, Crofford MJ, Amparo EG. Abnormalities of the neonatal brain: MR imaging. Part I. Intracranial hemorrhage. Radiology 1987;163:387-94.  Back to cited text no. 35
    
36.
Wolf A, Naylor K, Tam M, Habibi A, Novotny J, Liščák R, et al. Risk of radiation-associated intracranial malignancy after stereotactic radiosurgery: A retrospective, multicentre, cohort study. Lancet Oncol 2019;20:159-64.  Back to cited text no. 36
    
37.
Deora H, Tripathi M, Tewari MK, Ahuja CK, Kumar N, Kaur A, et al. Role of gamma knife radiosurgery in the management of intracranial gliomas. Neurol India 2020;68:290-8.  Back to cited text no. 37
[PUBMED]  [Full text]  




 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow